Kornimate/medical-research-clean huggingface dataset:
efficacy study of induction chemotherapy before surgery in operable non-small cell lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: this study is randomized phase iii trial designed to assess whether (preoperative) neoadjuvant chemotherapy followed by surgery plus adjuvant chemotherapy with gemcitabine and cisplatin (experimental treatment) improves 3-year disease-free survival, compared to surgery plus adjuvant chemotherapy with gemcitabine and cisplatin (standard treatment) in stage ib, iia, iib and t3n1 non-small cell lung cancer


Eligibility criteria:
inclusion criteria: * histologically or cytologically proven nsclc patients * all patients must have:clinical stage ib, iia, iib and t3n1 by mediastinoscopy, chest ct and pet-ct * 18 year of ages or older * ecog performance status 0-1 * uni-dimensionally measurable lesion by recist criteria * no prior chemotherapy or radiotherapy for nsclc * pre-operative fev1 ≥ 2.0 l evaluated within 28 days * adequate bone marrow function: hb \> 9.0 g/dl, wbc ≥ 4,000/μl, platelet count ≥ 100,000/μl * adequate liver and renal function: total bilirubin \< 2 x uln, ast/alt \< 3 x uln, serum creatinine ≤ 1.5 mg/dl, creatinine clearance ≥ 60 ml/min * written informed consent exclusion criteria: * superior sulcus tumor * prior malignancy except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer at least 5 years * uncontrolled systemic illness such as dm, chf, unstable angina or arrhythmia * recent myocardial infarction within 6 months * patients with post-obstructive pneumonia or serious infection * pregnant or nursing women (women of reproductive potential have to agree to use an effective contraceptive method.) * patients with psychological problem
the evaluation of orcel for the treatment of venous ulcers

Conditions: Venous Insufficiency; Leg Ulcer

Summary: this study was designed to confirm the clinical benefits and safety of orcel in the treatment of venous ulcers. orcel and standard care are compared to standard care alone. standard care consists of currently accepted compression therapy. patients are treated for 12 weeks. patients with healed ulcers are followed for an additional 12 weeks to assess durability of the healed wound.


Eligibility criteria:
inclusion criteria: * any race, between 18 and 85 years of age * male or female * chronic venous insufficiency * ulcer size between 2 and 20 sq cm, inclusive * ulcer present for at least one month * abi \>0.7 exclusion criteria: * decrease in wound size \>35% during screening phase * infection at ulcer site * uncontrolled diabetes mellitus * malnutrition * previous treatment with excluded medications

Keywords: venous leg ulcer venous insufficiency orcel
a follow-up study to evaluate the safety of retinostat® in patients with age-related macular degeneration

Conditions: Age-Related Macular Degeneration

Summary: the purpose of this study is to examine the long term safety of an experimental gene transfer agent, retinostat®, designed to treat neovascular age-related macular degeneration.


Eligibility criteria:
inclusion criteria: * must have received a subretinal injection of retinostat * must have been enrolled in protocol rs1/001/10 exclusion criteria: * did not receive retinostat® as part of the rs1/001/10 protocol
prevalence of mih among group of egyptians children aged from 8 to 12 in damietta

Conditions: Molar Incisor Hypomineralization

Summary: assesment of the prevalence of molar incisor hypomineralization among a group of egyptian children aged from 8 to 12 years old in damietta governate. this study will determine the severity of molar incisor hypomineralization which will help in its managment ,also will increase the awareness pf pediatric dentists about the prevalence of molar incisor hypomineralization in egyptian children.also it will allow the early detection of molar incisor hypomineralization which will make the parents seek early treatment for it. participants fromprimary schools in damietta governate will be included in the study. clinica examination will be carried out in the school lab or in embty class, in day light.


Eligibility criteria:
inclusion criteria: * positive subject acceptence for participation in the study. * children aged from 8 to 12 years old. * eruption of at least two first permanent molars. * both genders. exclusion criteria: * uncooperative child. * children with prthodontic appliances. * children with systemic diseases. * children suffering from any other type of enamel defect as enamel hypoplasia.
spine trauma in the elderly

Conditions: Spine Injury; Trauma; Surgery

Summary: our study aims at investigating short and long-term outcomes following surgery for subaxial spine injuries in the elderly (octogenarian) population.


Eligibility criteria:
inclusion criteria: * all patients surgically treated for subaxial spine injuries between 2006 and 2018 exclusion criteria: * missing records
eus-guided cryothermal ablation in patients with stage iii pancreatic adenocarcinoma (hybridtherm study)

Conditions: Pancreatic Adenocarcinoma Non-resectable

Summary: in patients with locally advanced tumour, neoadjuvant treatment has been proposed in various modalities as a way to decrease size and downstage the tumour leading to a re-sectable disease. the hybridtherm probe (htp), (erbe elektromedizin gmbh, tübingen, germany) combines bipolar rf-ablation with cryogenic induced cooling. a bipolar radiofrequency system creates ablation with less collateral thermal damage than standard monopolar systems but with the trade-off to lose overall efficiency.

about 40% of patients with pancreatic cancer have no metastasis at the moment of diagnosis, but in 20% of patients surgery is not feasible due to vascular invasion or poor general conditions. these patients with stage iii pancreatic cancer (locally advanced or borderline resectable) may benefit from neoadjuvant chemotherapy or chemoradiotherapy. the hybridtherm probe is a new, minimally invasive device that can be safely applied under eus guidance to locally ablate the pancreatic tissue adding a local efficacy to the systemic activity offered by chemotherapy and could give these patients a bigger chance of survival. the present study is an interventional randomized controlled phase ii/iii trial (device), that assigns patients into two groups: patients receiving standard chemotherapy alone and those receiving chemotherapy plus eus-guided hybridtherm ablation. the randomization is performed at the time of eus diagnosis and staging.

Eligibility criteria:
inclusion criteria: * pathological diagnosis * patients with borderline resectable/locally advanced pancreatic adenocarcinoma; * patients no previously treated with neoadjuvant treatments, irrespective of the regimen * age \>18 years; ≤ 80 * genders eligible for study: both * patients who can express their consent * karnofsky performance status \>70; * life expectancy \>6 months. * plt\>100000/mcl; inr\<1.5. * adequate renal function with a creatinine threshold * adequate bone marrow function (wbc ≥3500) exclusion criteria: * pregnancy * acute pancreatitis * patients having distant metastasis

Keywords: pancreatic adenocarcinoma cryothermoablation
forced lefthandedness in neonatal brachial plexus palsy (nbpp) children

Conditions: Neonatal Brachial Plexus Palsy

Summary: the aim of the project is to assess the neurophysiological and functional consequences of forced lefthandedness in a population with right neonatal brachial plexus palsy (nbpp).

a cross-sectional case-control study design to assess the neurophysiological and functional consequences of forced lefthandedness in a population with right neonatal brachial plexus palsy (nbpp). controls are natural lefthanded typical developing children and adolescents.case and controls are matched for age, gender and activity level.

Eligibility criteria:
inclusion criteria: * typical developing * lefthanded * nbpp or healthy * righthanded parents * 6-23 years exclusion criteria: * history of other locomotor or neurological disorder than nbpp * history of brain surgery * history of psychiatric disorder

Keywords: upper limb paresis developmental functiona laterality
drug coated balloon only vs drug eluting stent angioplasty

Conditions: Coronary Artery Disease

Summary: drug coated balloon (dcb) is a relatively new technology which allows the treatment of coronary artery disease without permanent implantation of a metallic scaffold (stent) in the coronary artery. it is recommended by international guidelines for the treatment of in-stent restenosis (i.e. when a previously implanted stent in the coronary artery develops narrowings again). data on patient outcomes of patients treated with dcb for de novo coronary artery disease (narrowings in artery supplying blood to the heart that has not been previously treated with a stent) are limited to relatively small studies. in our institution, dcbs have been used over the last 10 years and we have developed a large clinical database. we intend to compare the outcomes of all our patients treated clinically with dcb vs patients treated with drug eluting stent (des). we will, incorporate all patients presenting either with myocardial infarction (heart attack) or stable angina. our main outcomes will be: primary 1) mortality secondary 1) cardiac mortality 2) cardiac rehospitalisation3) composite of cardiac mortality and cardiac rehospitalisation


Eligibility criteria:
patients with coronary artery disease being treated with dcb or des

Keywords: drug coated balloon drug eluting stent
combo endoscopy oropharyngeal airway in sedated endoscopic retrograde cholangiopancreatography for patients

Conditions: Choledocholithiasis With Cholecystitis With Obstruction; Obstructive Jaundice; Pancreatitis; Cholelithiasis

Summary: hypoxia represents the prevailing adverse occurrence during the sedation of patients undergoing endoscopic retrograde cholangiopancreatography (ercp) with propofol. a recent innovation in this domain is the combo endoscopy oropharyngeal airway-a multifaceted device that encompasses capnography monitoring, bite block , oxygenation support, and oropharyngeal airway management. this device has been purposefully designed to cater to the unique requirements of endoscopic procedures. the principal objective of this study is to assess the efficacy of the combo endoscopy oropharyngeal airway in reducing the incidence of hypoxia in patients undergoing ercp under sedation.


Eligibility criteria:
inclusion criteria: * age ≥18 years； * the asa classification ranges from i to iii. * patients have signed the informed consent form. * patients scheduled to undergo sedated ercp examination; * the estimated duration of the procedure does not exceed 45 minutes. exclusion criteria: 1. patients with coagulation disorders, tendency for oral/nasal bleeding, mucosal injury/occupying lesions, or difficult oropharyngeal airway insertion making airway management unfeasible; 2. severe cardiac dysfunction (\<4 mets); 3. severe renal insufficiency (requiring preoperative dialysis); 4. child-pugh class c; 5. diagnosed chronic obstructive pulmonary disease (copd) or other acute/chronic pulmonary diseases requiring long-term/intermittent oxygen therapy; 6. increased intracranial pressure; 7. upper respiratory tract infections (oral/nasal/pharyngeal); 8. fever (core temperature \>37.5°c); 9. confirmed pregnancy or current breastfeeding; 10. allergy to sedatives (e.g., propofol) or medical adhesives; 11. emergency procedures; 12. multiple trauma injuries; 13. peripheral oxygen saturation (spo2) levels below 95% while breathing room air preoperatively; 14. bmi \ 30 kg/m²; 15. current participation in other clinical trials; 16. other conditions deemed ineligible by investigators.

Keywords: respiratory depression the combo endoscopy oropharyngeal airway hypoxia sedation ercp
moxibustion in osteoarthritis of the knee

Conditions: Knee Osteoarthritis

Summary: this is a multicenter , double-blinded, double-dummy, randomized controlled clinical trial to evaluate the efficacy of moxibustion for osteoarthritis of the knee.

aim: to evaluate the effectiveness of moxibustion treatment for patients with osteoarthritis of the knee, with respect to relieving pain, improving the dysfunction and improving their quality of life as well. design: a multicentre, double-blinded, double-dummy, randomized controlled clinical study will be performed in china. eligible participants will be randomly assigned to moxibustion group (real moxibustion plus placebo gel) and the control group (diclofenac sodium gel plus sham moxibustion) with a 1:1 allocation ratio. participants in both groups will receive 12 sessions of real/sham moxibustion in 4 weeks at 3 acupoints (st35, ex-le4, st36 ). either diclofenac sodium gel or placebo gel will be applied 4 g per knee 4 times daily for 4 weeks. the whole study period is 13 weeks, with a 1-week run-in period, 4-week treatment phase, and 8-week follow-up phase. the primary outcome measure will be the change of the global scale of the western ontario and mcmaster universities osteoarthritis index (womac) at the end of the course. the secondary outcomes include the change of other subscales (pain, stiffness, and function) of womac, visual analogue scale (vas) and patient global assessment (pga). safety will be assessed at every visit.

Eligibility criteria:
inclusion criteria: * male or female, aged between 40 and 75 years, with knee osteoarthritis diagnosed according to american college of rheumatology criteria * radiologic confirmation of osteoarthritis in 1 or both knees (kellgren-lawrence score 2 or 3) * had knee pain in one or both knee(s) of longer than 3 months'duration * the average severity of knee pain at least 3 points on a10-point of visual analogue scale(vas) * never experienced moxibustion before this trial * participants who are willing to comply with our study protocol * participants who agree to sign the consent form exclusion criteria: * subjects with serious diseases including cancer, uncontrolled hypertension, diabetes mellitus requiring insulin injection, life-threatening cardiovascular or neurological events, chronic respiratory disease, a haemorrhagic disorder and serious mental diseases * subjects had pain in the knee may caused by inflammatory, malignant, autoimmune disease or traumatic injury; * subjects received knee replacement surgery for the affected knee * subjects received knee arthroscopy within the past year, steroid or hyaluronic acid injection in the knee joints within the previous 3 months * subject who currently participate in another clinical trial * subjects received physiotherapy or other treatments for osteoarthritis knee pain (with the exception of non-steroidal anti-inflammatory drugs) during the previous 4 weeks;

Keywords: knee osteoarthritis moxibustion diclofenac sodium gel
comparison of outcomes after laparoscopic versus open appendectomy in acute appendicitis

Conditions: Appendectomy; Pain, Postoperative; Length of Stay

Summary: a comparison study was performed between laparoscopic appendectomy and open appendectomy in acute setting in tertiary hospital to access the outcome of postoperative pain and hospital stay. as the popularity of laparoscopic appendectomy has failed in major tertiary hospital due to huge amount of patient load in which open appendectomy was performed.this study was performed to prove that outcome of laparoscopic appendectomy are far better than open appendectomy and to increase the use of laparoscopic surgery in acute settings

introduction: open appendicectomy has been a safe and usually opted mode of operation for acute appendicitis for more than a century, but since last 10 years laparoscopic appendicectomy is gaining popularity, although still not as popular as laparoscopic cholecystectomy. comparison of these two is studied in terms of pain outcome as patient perceives and length of hospital stay. objectives: the objective of this study was to compare the outcome of open appendectomy and laparoscopic appendectomy in patients with acute appendicitis. study design: randomized control trial setting: surgical unit i, services hospital, lahore duration of study: duration of my study was six months after the approval of synopsis i.e 21-02-2015 to 20-08-2015. sample size: was calculated using who method of calculating sample size. sampling technique: non probability consecutive sampling. data collection procedure: all patients fulfilled the inclusion criteria was admitted through the emergency after taking approval from hospital ethical committee. a detailed history had been taken including demographic data (age, address). patients was requested to sign an informed consent. they had been assured regarding confidentiality and expertise used for the procedure. all procedures was done by a single operating surgical team to control bias. all the data/variables was recorded on a specially designed performa attached which are post-op pain at 12hrs and 24 hrs, post-op stay and patient satisfaction score.

Eligibility criteria:
inclusion criteria: * with acute appendicitis confirmed clinically by pain in right iliac fossa accompanied by right iliac fossa tenderness, elevated leukocyte count (\>8\*109/ml) without a palpable mass and on radiological investigation admitted through emergency department were included in the study. exclusion criteria: * • perforated appendix (had been assesses on abdominal ultrasound or per-operatively. * palpable mass in the right lower quadrant as assessed by clinical exam. * history of co-morbidities e.g. known diabetic, known hypertensive, cirrhosis as shown by ultrasonography and coagulation disorder (to be determined by low platelet count; \<140 \*109, deranged pt and aptt).(pt=13sec, aptt= 33 sec) * patients unfit for surgery (asa grade iii/iv). * patient who did not give informed consent.

Keywords: open appendectomy laparoscopic appendectomy post-operative pain hospital stay
mri screening for patients with myelodysplastic syndrome (mds), who have received multiple red blood cell transfusions

Conditions: Myelodysplastic Syndrome (MDS)

Summary: a known risk of red blood cell transfusions is that it puts excess iron into the patient's body. researchers are continually seeking the most effective method of measuring iron concentration. the purpose of this study is to determine how much iron has been deposited in a patient's heart and liver as a result of having received red blood cell transfusions using magnetic resonance imaging (mri).


Eligibility criteria:
inclusion criteria: * male or female patients will need documentation of diagnosis of myelodysplastic syndrome by previous bone marrow exam * male or female patients with mds who have received at least 50 units of red blood cell transfusions. * serum ferritin \> 1,000 * written informed consent by the patient. exclusion criteria: * contraindication to mri, including cardiac pacemaker, brain aneurysm clip, implanted neurostimulator, insulin pump, cochlear implant, metal slivers in the eyes, intrauterine device or any other mri incompatible metal implants or intractable claustrophobia.
clinical safety and preliminary efficacy of mage-a4 tcr gene-modified t cells to treat malignant tumors

Conditions: Malignant Solid Tumors

Summary: the purpose of this study is to evaluate the clinical safety and preliminary efficacy of mage-a4 tcr gene-modified t lymphocytes in the treatment of malignant solid tumor patients, such as malignant melanoma and lung cancer.


Eligibility criteria:
inclusion criteria: * sex: male or female * age: from 18 to 80 years * patients must have histologically confirmed solid tumors that have failed standard therapies (surgery, chemotherapy, radiotherapy) and for which no curative options exist, including, but not limited to: non-small cell lung carcinoma malignant melanoma esophageal carcinoma head and neck carcinoma * hla-a\*24:02 * mage-a4 positive in the test by rt-pcr on tumor tissue or immunohistochemistry of resected tissue of the patient. * ps ecog 0 or \<2 * laboratory tests results 7 days before the start of treatment: white blood cells: more than 3.0 × 109/l platelets: more than 100 × 109/l neutrophils: more than 1.5 × 109/l hemoglobin: more than 80g/l serum glutamate pyruvate transaminase: less than 2.5 folds of the upper normal limit (uln) serum glutamic-oxal (o) acetic transaminase: less than 2.5 × uln serum bilirubin: less than 1.25 × uln serum creatinine: less than 1.25 × uln * pregnancy test: the test of women of child-bearing period must be negative 7 days before the start of treatment * contraception: male and female subjects of child-bearing period must adopt a reliable method of contraception before entry into this study until 30 days after stopping this study * informed consent: subject must have the ability to understand and voluntarily sign a written informed consent exclusion criteria: * patients with life-threatening condition or complication other than their basic disease * pregnant or lactation. patients both males and female with reproductive potential (i.e. menopausal for less than 1 year and not surgically sterilized) must practice effective contraceptive measures throughout the study. women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration * active systemic infections * history of neoplasms: other neoplasms * medical history: active cns disease, or congestive heart failure, or severe coronary artery disease, or cardiac arrhythmias, or concomitant corticosteroid therapy * metastasis: clinical symptoms of brain metastasis * other clinical trial: the subject received other clinical trial before this study * laboratory tests: the serum test of human immunodeficiency virus, or hepatitis b virus, or hepatitis c virus was positive * compliance: poor compliance